---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052052"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-03T00:24:05.389139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx Q1 2024 revenue $109M (+8% YoY); net loss $171M; reaffirms guidance; pipeline advances

## Summary
- Q1 total revenue $109M (+8% YoY); Crysvita $83M (+9%), Dojolvi $16M (+14%).
- Net loss $171M ($2.03 per share) vs $164M ($2.33) in Q1 2023; operating expenses $274M.
- Reaffirmed 2024 guidance: total revenue $500-530M, Crysvita $375-400M, Dojolvi $75-80M, cash use <$400M.
- Positive interim Phase 1/2 GTX-102 data for Angelman syndrome; OI Phase 3 enrollment complete; DTX401 data expected Q2 2024.
- Cash and equivalents $569M as of March 31, 2024; net cash used in operations $191M in Q1.

## SEC filing metadata
- accession: 0000950170-24-052052
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/0000950170-24-052052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/rare-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052052
- JSON: https://secwatch.observer/filing/0000950170-24-052052.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052052.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported quarter ended March 31, 2024 results: revenue $109 million, net income net loss of $171 million, or $2.03 per share basic and diluted, EPS $2.03 per share basic and diluted. Guidance reaffirmed.
  - Period: quarter ended March 31, 2024
  - Revenue: $109 million
  - Net income: net loss of $171 million, or $2.03 per share basic and diluted
  - EPS: $2.03 per share basic and diluted
  - Guidance: reaffirmed
  - Result: reported results
  source text: Pharmaceutical Inc. Investors Joshua Higa ir@ultragenyx.com Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017024052052/0000950170-24-052052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.